Artivion | CRY - Los Gastos De Explotación





Los Gastos De Explotación Cambio Fecha
Abbott USD 11.66B 1.2B 2026-09
Accuray USD 37.18M 567K 2024-12
AngioDynamics USD 81.95M 1.68M 2025-09
Artivion USD 111.2M 9.45M 2025-12
AtriCure USD 143.94M 3.22M 2026-06
Baxter International USD 2.68B 3.36B 2026-06
Becton, Dickinson and Co. USD 24.42B 283M 2026-06
Boston Scientific USD 4.2B 49M 2026-06
Edwards Lifesciences USD 1.22B 87.6M 2026-06
Inogen USD 49.14M 665K 2024-09
Integra LifeSciences USD 368.53M 674.84M 2026-09
J&J USD 18.93B 1.09B 2026-09
Mesa Laboratories USD 33.98M 2.03M 2024-12
Orthofix International USD 213.79M 12.36M 2025-12
Pfizer USD 85.19B 4.91B 2026-06
ResMed USD 1.01B 83.57M 2026-06
Stryker USD 4.8B 118M 2026-06
Tandem Diabetes Care USD 268.35M 3.7M 2026-06
Teleflex USD 2.9B 179.9M 2026-06
Terumo JPY 222.33B 46.54B 2026-06
Trinity Biotech USD 12.38M 2.44M 2025-12